Invivyd, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IVVD | VALN | INO | TVGN | ENTA | NNVC | |
|---|---|---|---|---|---|---|
| Market cap | 186.76M | 533.86M | 167.50M | 95.87M | 310.19M | 35.24M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.2 | 4.7 | -3.9 | — | -4.5 | -3.9 |
| Price/book | 1.0 | 5.9 | 30.6 | -1.4 | 3.1 | 3.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −61.71% | −38.78% | −27.51% | −75.61% | −5.04% | −27.41% |
| Today | +8.96% | +2.18% | −2.41% | −3.38% | +2.70% | −3.50% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IVVD news ›Invivyd Unveils Measles Antibody Candidate VMS063 at IDWeek 2026
Presented by The Community Oncology Alliance Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro. Invivyd announced preclinical data supporting VMS063,…
More from 1 other outlet
Invivyd (NASDAQ:IVVD) vs. Viridian Therapeutics (NASDAQ:VRDN) Head to Head Comparison
Posted by Mitch Edgeman on Nov 1st, 2026 Invivyd (NASDAQ:IVVD – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies…
More from 1 other outlet
Arms race: new ammunition in the fight against viral antibody escape
The concept of viral escape from antibody neutralization seems intimately familiar in our post-COVID world—it’s the reason that we wait in line for new iterations of vaccines while dreadingthe ... Arms race: new ammunition in the fight…
Analysts Have Conflicting Sentiments on These Healthcare Companies: PROCEPT BioRobotics (PRCT), Invivyd (IVVD) and Alpha Tau (DRTS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PROCEPT BioRobotics (PRCT), Invivyd (IVVD) and Alpha Tau (DRTS). BTIG analyst Ryan Zimmerman maintained a Hold rating on PROCEPT BioRobotics…
Engineered antibodies show promise for blocking PRRSV entry in pigs
A new review maps PRRSV entry targets and argues that engineered antibodies against GP4 and the essential receptor CD163 offer the most promising route to broad antiviral protection. Subject of Research: Engineered antibody strategies for…
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the initiation of FLINTLOCK, a Phase 2 clinical trial evaluating the safety, tolerability, pharmacokinetics, and…
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated pote... Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the…
Invivyd (NASDAQ:IVVD) and Arcus Biosciences (NYSE:RCUS) Critical Contrast
Posted by Tristan Rich on Oct 19th, 2026 Arcus Biosciences (NYSE:RCUS – Get Free Report) and Invivyd (NASDAQ:IVVD – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses…
Moderna designs bispecific antibodies against SARS-CoV-2 variants
Scientists at Moderna Inc. are seeking a solution to the rapid emergence of viral variants that escape treatments. Many monoclonal antibodies (mAbs) initially work well against a single target but lose efficacy as viruses such as…
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com7
- themarketsdaily.com2
- defenseworld.net1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.